ANCHORS Alcohol & Sexual Health Study: UH3 Project
NCT04331704
Recruiting
80 young adult men will complete an initial survey and receive 1 of 2 types of alcohol and sexual health education and information to encourage prevention of alcohol-related problems, HIV and other sexually transmitted infections (STIs). Participants will then take pre-exposure prophylaxis (PrEP) for HIV prevention and complete a daily 5-minute, telephone-based interactive voice response (IVR) assessment of alcohol/substance use, sexual behavior and PrEP taking for 30 days. Medication will all b... Read More
Gender:
MALE
Ages:
Between 18 years and 30 years
Trial Updated:
07/09/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Alcohol Use, Unspecified, Substance Use, Sex Behavior
Register for Updates
Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis
NCT04362644
Recruiting
The purpose of the study is to see if imaging with fluorine-18 Fluorodeoxyglucose (\[18F\] FDG) and fluorine-18 Displacement Per Atom (\[18F\]DPA-714) using positron emission tomography and computed tomography (PET/CT) will show lung inflammation and fibrosis in patients diagnosed with idiopathic pulmonary fibrosis (IPF). This study may help physicians and researchers better understand how best to treat patients with IPF in the future.
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
07/09/2025
Locations: The University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
Identify Proteomic Biomarkers for Outcome Prediction of Locoregional Treatments for HCC
NCT04459468
Recruiting
This study will enroll patients with hepatocellular carcinoma being planned for TACE or other standard of care treatment (such as denovo ablation or Y90) and obtain blood samples pre and post treatment procedure for biomarker identification using bead based X-aptamer library. No intervention is planned.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/09/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Hepatocellular Carcinoma
Register for Updates
Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC
NCT04470024
Recruiting
This is a phase Ib study with a safety lead-in (n = 6 per arm) evaluating combinatorial DPV-001 + sequenced PD-1 blockade, with or without GITR agonist, in recurrent or metastatic HNSCC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: Portland Providence Medical Center, Portland, Oregon
Conditions: Cancer of the Head and Neck
Register for Updates
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
NCT04499248
Recruiting
This is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-groups (Cohort 2) and (Cohort 3) study to evaluate the safety and efficacy of AGN-193408 SR in participants with open-angle glaucoma or ocular hypertension
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: Horizon Eye Specialists & Lasik Center - Sun City /ID# 252153, Sun City, Arizona +45 locations
Conditions: Open-angle Glaucoma, Ocular Hypertension
Register for Updates
Longitudinal Neuroimaging in Sturge-Weber Syndrome
NCT04517565
Recruiting
In this project the accuracy of a novel, rapid magnetic resonance imaging (MRI) approach to detect brain abnormalities in patients with Sturge-Weber syndrome (SWS) will be tested; this new imaging approach, that can create multiple types of MR images in about 5 minutes, without contrast administration (and sedation even in young children), can be also readily applied in other pediatric brain disorders in the future. The investigators will also study how advanced MRI, including susceptibility-wei... Read More
Gender:
ALL
Ages:
Between 3 months and 30 years
Trial Updated:
07/09/2025
Locations: Wayne State University / Children's Hospital of Michigan, Detroit, Michigan
Conditions: Sturge-Weber Syndrome
Register for Updates
Investigation of Brain Mechanisms Involved in the Urinary Continence Mechanism Associated With Aging
NCT04599088
Recruiting
Urge urinary incontinence (UUI) is a common problem in older people which vastly reduces quality of life, yet the cause and mechanism of disease are not well understood. This study will characterize brain control of the bladder in young and old continent individuals and age-matched incontinent counterparts. This will expand the investigators current knowledge of how the brain controls the bladder, how that control changes with age and disease, and suggest new targets to guide development of bett... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Urgency Urinary Incontinence
Register for Updates
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
NCT04732065
Recruiting
This phase I trial studies the effects and best dose of ONC206 alone or in combination with radiation therapy in treating patients with diffuse midline gliomas that is newly diagnosed or has come back (recurrent) or other recurrent primary malignant CNS tumors. ONC206 is a recently discovered compound that may stop cancer cells from growing. This drug has been shown in laboratory experiments to kill brain tumor cells by causing a so called "stress response" in tumor cells. This stress response c... Read More
Gender:
ALL
Ages:
Between 2 years and 21 years
Trial Updated:
07/09/2025
Locations: University of California, San Francisco, San Francisco, California +4 locations
Conditions: Diffuse Midline Glioma (DMG), Glioblastoma, Recurrent Ependymoma, Spinal Cord Glioma, Recurrent Malignant Central Nervous System Neoplasm, CNS Tumor, Central Nervous System Tumor, World Health Organization (WHO) Grade III Glioma
Register for Updates
Danazol for Treatment of Cytopenias in Patients With Cirrhosis
NCT04873102
Recruiting
This is a phase II pilot study designed to assess the safety and efficacy of danazol for treatment of cytopenias in patients with CPC A/B cirrhosis. Subjects with or without telomere mutations and/or shortened telomeres will be treated with danazol 600 mg per day by mouth for a duration of 24 months. The goal will be to treat a total of 10 patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: Keck Hosital of USC, Los Angeles, California
Conditions: Cirrhosis, Liver, Cytopenia
Register for Updates
Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder
NCT04982796
Recruiting
This is a proof-of-concept randomized clinical trial of psilocybin-enhanced psychotherapy versus treatment-as-usual among individuals being treated for methamphetamine use disorder.
Gender:
ALL
Ages:
Between 25 years and 65 years
Trial Updated:
07/09/2025
Locations: Portland VA Health Care System, Vancouver, Washington
Conditions: Amphetamine-Related Disorders
Register for Updates
Physical Activity, Cardiac and Skeletal Muscle Energetics in Healthy Subjects and HFpEF Patients
NCT04998877
Recruiting
This research is being done to better understand the relationship between information collected by wearable devices and clinical measurements in people with heart failure with preserved ejection fraction (HFpEF) and others without HFpEF. This is an observational study with no study intervention or randomization. Participants will undergo baseline history and physical, 12-lead EKG, laboratory studies of blood/serum/urine, echocardiography, activity questionnaire, 6 minute walk test, and placemen... Read More
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
07/09/2025
Locations: Johns Hopkins Hosptial, Baltimore, Maryland
Conditions: Heart Failure With Preserved Ejection Fraction
Register for Updates
Vaccine Responses to SARS-CoV-2 and Other Emerging Infectious Diseases
NCT05078905
Recruiting
Background: Vaccines against SARS-CoV-2, the virus that causes COVID-19, have been highly effective against preventing severe disease. But the protective effects of these vaccines appear to wane over time. Researchers want to learn why. Objective: To learn more about how the immune system responds to vaccines against infections like SARS-CoV-2. Eligibility: Healthy adults ages 18 or older who are scheduled to receive either a new vaccine or a booster shot against SARS-COV-2 or another emerg... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: COVID-19, Vaccination, Healthy Volunteer
Register for Updates